This week’s recap highlights several significant FDA developments. We also cover ongoing successes of pembrolizumab with chemotherapy in NSCLC.

Both the SPOTLIGHT study (Vyloy plus the combination of mFOLFOX6 chemotherapy regimen of oxaliplatin, leucovorin, and ...

1 In adjusted analyses, researchers found that omitting the 5-FU bolus from FOLFOX (leucovorin calcium, fluorouracil, and oxaliplatin), FOLFIRI (leucovorin calcium, fluorouracil, and irinotecan ...